- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
- Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease . . .
Targeted DNA Methylation Using Modified DNA Probes: A Potential Therapeutic Tool for Depression and Stress-Related Disorders, International Journal of Molecular Sciences, 26, 12, (5643), (2025
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor 21,22 Tezepelumab administered subcutaneously at a dose of 210 mg every 4
- Recently Published - The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
- Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
- Encorafenib, Cetuximab, and mFOLFOX6 in - The New England Journal of . . .
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Preclinical and observational studies suggest that exercise may improve cancer outcomes However, definitive level 1 evidence is lacking In this phase 3, randomized trial conducted at 55 centers,
- Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease
Xenotransplantation offers a potential solution to the organ shortage crisis A 62-year-old hemodialysis-dependent man with long-standing diabetes, advanced vasculopathy, and marked dialysis-access
|